Direct muscarinic agonists bind and activate muscarinic receptors without requiring hydrolysis of acetylcholine (ACh) or inhibition of acetylcholinesterase (AChE). As a class, they are structurally related to ACh but modified to resist hydrolysis by AChE and, in most cases, butyrylcholinesterase (BuChE). The clinical applications of this drug class are narrow and tightly defined by organ-level muscarinic receptor pharmacology: urinary tract, gastrointestinal (GI) tract, eye, airways, and exocrine glands each contribute one or two distinct indications.
Bethanechol. Bethanechol is a quaternary ammonium carbamic acid ester of beta-methylcholine. It is selective for muscarinic receptors, has no meaningful nicotinic activity, and is resistant to hydrolysis by both AChE and BuChE, giving it a substantially longer duration of action than ACh. Because it is a quaternary compound, it does not cross the blood-brain barrier (BBB) and produces no central nervous system (CNS) effects at therapeutic doses. Oral bioavailability is poor (approximately 5 to 10 percent) and erratic, and the drug is administered orally or by subcutaneous injection; intravenous and intramuscular routes are avoided because they provoke severe systemic cholinergic reactions including profound bradycardia, hypotension, and bronchospasm. The primary clinical indication is non-obstructive urinary retention, including postoperative and postpartum urinary retention and neurogenic bladder with impaired detrusor contractility. A secondary indication is symptomatic relief of GI hypomotility in conditions such as postoperative ileus and gastroparesis, although prokinetic agents are generally preferred. Bethanechol is absolutely contraindicated in mechanical bowel or urinary obstruction, in peptic ulcer disease (risk of increased gastric acid secretion through M1 and M3 receptors), and in patients with asthma or chronic obstructive pulmonary disease (COPD) due to the risk of M3-mediated bronchoconstriction.1
Carbachol. Carbachol (carbamylcholine) is a carbamic ester of choline that retains both muscarinic and nicotinic agonist activity, distinguishing it from bethanechol. Like bethanechol, it is a quaternary compound, does not penetrate the BBB, and is resistant to cholinesterase hydrolysis. Its combined muscarinic and nicotinic activity limits systemic clinical utility, but makes it useful for intraocular applications where both M3-mediated miosis (pupillary constriction) and nicotinic effects on the ciliary body contribute to intraocular pressure (IOP) reduction. Intraocular carbachol is instilled directly into the anterior chamber during cataract surgery to produce miosis at the time of lens implantation, ensuring that the pupil is contracted before closure of the incision. Topical carbachol eye drops are a second-line treatment for open-angle glaucoma when pilocarpine is inadequate or not tolerated.1 Systemic absorption from topical ocular administration is minimal, but the prescriber should be aware that prolonged topical use may cause retinal detachment through traction by the ciliary body musculature in susceptible patients.
Pilocarpine. Pilocarpine is a naturally occurring tertiary amine alkaloid derived from the leaves of Pilocarpus jaborandi. As a tertiary amine, it crosses lipid membranes, including the BBB, making it the only direct muscarinic agonist in clinical use with meaningful CNS penetration. Its primary pharmacological actions are M3-mediated: miosis, ciliary muscle contraction (accommodation for near vision), and stimulation of exocrine gland secretion. The principal clinical uses are the treatment of open-angle glaucoma (as topical eye drops or controlled-release ocular insert, lowering IOP by improving trabecular meshwork outflow through ciliary muscle contraction), emergency reduction of IOP in acute angle-closure glaucoma (where rapid miosis relieves pupillary block), and the treatment of xerostomia (dry mouth) secondary to Sjogren syndrome or radiation therapy to the head and neck. At the dose used for xerostomia (5 mg orally three times daily), pilocarpine stimulates residual salivary gland M3 receptors, increasing salivary secretion. The most frequent adverse effects are dose-related: diaphoresis (sweating) from eccrine sweat gland M3 stimulation, flushing, and increased urinary frequency. Because pilocarpine crosses the BBB, CNS adverse effects including headache, visual disturbances, and, at toxic doses, seizures are possible. Pilocarpine is contraindicated in acute iritis and in patients with uncontrolled asthma, since M3-mediated bronchoconstriction may precipitate bronchospasm.2
Methacholine. Methacholine is a synthetic quaternary derivative of ACh with selective muscarinic activity and a substantially longer duration of action than ACh due to its resistance to AChE hydrolysis (though it remains susceptible to BuChE). Its only established clinical use is the methacholine bronchoprovocation test, a standardized inhalational challenge used to assess airway hyperresponsiveness and diagnose asthma in patients with normal spirometry at rest. In the test, incremental concentrations of inhaled methacholine are delivered; airway smooth muscle M3 receptor stimulation produces bronchoconstriction in proportion to baseline hyperresponsiveness. A fall in forced expiratory volume in one second (FEV1) of 20 percent or more from baseline defines a positive test, establishing the provocative concentration of methacholine required to produce this response (PC20). Patients with asthma have significantly lower PC20 values than normal subjects, reflecting their exaggerated bronchoconstrictor response. The test is sensitive but not highly specific: a negative test effectively excludes current asthma, while a positive test requires clinical correlation because airway hyperresponsiveness also occurs in allergic rhinitis, recent viral upper respiratory infections, and COPD. Inhaled bronchodilators must be withheld before testing, and short-acting beta-2 agonists must be on hand throughout to reverse any severe bronchoconstriction.3
Cevimeline. Cevimeline is a quinuclidine derivative with selective M1 and M3 agonist activity, developed specifically for the treatment of xerostomia in Sjogren syndrome. Compared with pilocarpine, cevimeline has a longer duration of action (given three times daily versus three to four times daily for pilocarpine), somewhat greater receptor selectivity for the salivary gland M3 and M1 subtypes, and a somewhat lower rate of diaphoresis as an adverse effect, though the clinical superiority over pilocarpine in head-to-head comparisons is modest. Cevimeline is a tertiary amine and crosses the BBB, so CNS adverse effects are possible at high doses. It is metabolized by CYP2D6 (cytochrome P450 isoform 2D6) and CYP3A4 (cytochrome P450 isoform 3A4), and clinically relevant pharmacokinetic drug-drug interactions with potent inhibitors of these enzymes (fluoxetine, paroxetine for CYP2D6; azole antifungals, clarithromycin for CYP3A4) can increase cevimeline exposure and the risk of cholinergic adverse effects. Cevimeline should be used with caution in patients with narrow-angle glaucoma, asthma, and cardiac conduction disease, mirroring the contraindication profile of pilocarpine.2
Bethanechol: non-obstructive urinary retention and GI hypomotility; quaternary, no CNS effects; avoid in obstruction, asthma, peptic ulcer disease. Pilocarpine: open-angle and acute angle-closure glaucoma; xerostomia (Sjogren, radiation); tertiary amine, crosses BBB; diaphoresis is dose-limiting. Carbachol: intraocular miosis during cataract surgery; second-line glaucoma. Methacholine: bronchoprovocation challenge only (diagnostic, not therapeutic). Cevimeline: Sjogren xerostomia; M1/M3-selective; longer duration than pilocarpine; CYP2D6/3A4 substrate.
The peripheral AChE inhibitors share a structural feature that prevents CNS (central nervous system) penetration: they are quaternary ammonium compounds with permanent positive charges that cannot traverse the BBB (blood-brain barrier). This pharmacokinetic limitation is actually a clinical advantage in most of their indications, because the goal is to enhance neuromuscular junction (NMJ) and autonomic cholinergic transmission without producing central cholinergic effects. Neostigmine, pyridostigmine, and edrophonium differ primarily in their onset, duration of action, and mechanism of AChE inhibition.
Mechanism of AChE Inhibition: Carbamylation vs. Ionic Binding. Neostigmine and pyridostigmine inhibit AChE by carbamylation of the catalytic serine residue at the esteratic site. The drug molecule binds to the active site and transfers its carbamyl group to the serine hydroxyl, forming a carbamylated enzyme intermediate that is hydrolyzed much more slowly than the normal acetyl-enzyme intermediate, effectively blocking the enzyme for minutes to hours (neostigmine approximately 30 to 60 minutes, pyridostigmine somewhat longer). This is termed reversible inhibition because the enzyme eventually regenerates, though much more slowly than with ionic (non-covalent) inhibition. Edrophonium inhibits AChE by a purely ionic, non-covalent mechanism: the positively charged quaternary nitrogen forms an electrostatic bond with the anionic site of AChE, while a hydroxyl group forms a hydrogen bond with the esteratic site, blocking substrate access without forming a covalent intermediate. This non-covalent binding is extremely short-lived, giving edrophonium an onset of action within seconds and a duration of only 5 to 10 minutes, properties that define its diagnostic rather than therapeutic role.4
Neostigmine. Neostigmine is the prototypical peripheral AChE inhibitor with a balanced profile across NMJ, autonomic ganglionic, and postganglionic cholinergic synapses. At the NMJ, it prolongs ACh residence in the synaptic cleft, increasing the probability of receptor activation at the remaining functional NMJ endplates, which is the basis for its use in myasthenia gravis (MG) and in reversal of non-depolarizing neuromuscular blockade (NMB). As a quaternary compound, it does not cross the BBB, but it freely crosses into the peripheral autonomic nervous system and produces muscarinic side effects including bradycardia, increased salivation, bronchospasm, increased gastrointestinal (GI) motility and secretion, and increased bladder detrusor tone. In clinical practice, neostigmine administered for NMB reversal or MG treatment is typically co-administered with glycopyrrolate or atropine to blunt these muscarinic peripheral effects while preserving the desired nicotinic NMJ effect; glycopyrrolate is preferred because, as a quaternary compound itself, it does not cross the BBB and does not interfere with the desired NMJ action. Oral bioavailability of neostigmine is very poor (approximately 1 to 2 percent), so the oral formulation requires substantially higher doses than parenteral formulations to achieve comparable plasma levels. The drug is also used to reverse postoperative urinary retention (intramuscular or subcutaneous route) and in the management of acute colonic pseudo-obstruction (Ogilvie syndrome), where intravenous neostigmine produces dramatic decompression of the dilated colon.47
Pyridostigmine. Pyridostigmine is structurally and pharmacologically similar to neostigmine but has a longer duration of action (3 to 6 hours oral versus 1 to 2 hours for neostigmine), making it the preferred oral agent for the long-term management of MG. The standard oral formulation (Mestinon, 60 mg tablets) and a sustained-release formulation (Mestinon Timespan, 180 mg) give clinicians flexibility in dosing frequency to match the patient's fluctuating symptom pattern, particularly the characteristic morning weakness on waking before the first dose takes effect. Pyridostigmine at the doses used for MG does not produce significant CNS effects due to its quaternary structure, but muscarinic peripheral effects (increased secretions, GI cramping, diarrhea, muscle cramping from increased NMJ activity) are common dose-limiting adverse effects. Dose titration in MG management requires balancing symptomatic improvement (NMJ effect) against tolerability (muscarinic side effects), and the distinction between a cholinergic crisis (overdose with excessive NMJ depolarization producing weakness from depolarizing block) and a myasthenic crisis (insufficient drug with worsening autoimmune block) is a critical clinical decision point that is discussed further in Section 3. Pyridostigmine has also been used as a nerve agent pretreatment (reversible AChE occupancy reduces the number of AChE sites available for irreversible organophosphate [OP] binding), though the evidence for its prophylactic efficacy is limited.4
When neostigmine is given for NMB reversal, the muscarinic peripheral effects (especially bradycardia) must be attenuated. Glycopyrrolate is the preferred anticholinergic co-agent because: (1) it is quaternary and does not cross the BBB, avoiding CNS effects; (2) it has a similar onset of action to neostigmine (2 to 3 minutes IV), allowing simultaneous administration; (3) unlike atropine, it does not cause the initial bradycardia that can precede atropine's peak effect. Atropine is an acceptable alternative but its slower, more variable onset can transiently worsen bradycardia before its effect peaks. Standard NMB reversal dosing: neostigmine 0.04 to 0.07 mg/kg IV + glycopyrrolate 0.01 mg/kg IV given simultaneously.
Edrophonium's ultrashort duration of action, which limits its therapeutic use, is the pharmacological feature that makes it diagnostically valuable. A brief, reversible enhancement of neuromuscular junction (NMJ) cholinergic transmission identifies patients whose weakness is caused by insufficient acetylcholine receptor (AChR) activation and confirms the diagnosis of myasthenia gravis (MG), while providing a built-in safety profile in that its effects resolve within minutes if adverse reactions occur.
The Tensilon Test Protocol. The edrophonium challenge test, historically called the Tensilon test after the proprietary name of the original edrophonium preparation, is performed by administering edrophonium chloride intravenously in a controlled setting with atropine and resuscitation equipment immediately available. The standard adult protocol involves an initial test dose of 2 mg IV injected over 15 to 30 seconds, with observation for one minute. If no adverse reaction (severe bradycardia, bronchospasm, syncope) occurs, the remaining dose of 8 mg IV is administered, for a total of 10 mg. A positive test is defined as objectively demonstrable transient improvement in a quantifiable sign of weakness: ptosis lifting, improvement in extraocular muscle range, increased grip strength, or improvement in dysarthria or dysphagia, with all changes resolving within 5 to 10 minutes as the drug is eliminated. The test carries risks: cholinergic adverse effects including bradycardia (which may be severe, particularly in older patients or those with preexisting cardiac conduction disease) and syncope from nicotinic ganglionic effects require that the test always be performed with a physician and cardiac monitoring present, atropine drawn up and ready, and intravenous access secured.6
Interpretation of the Edrophonium Test. The sensitivity of the edrophonium test for MG is approximately 80 to 90 percent in generalized MG but lower (approximately 60 percent) in purely ocular MG, reflecting the smaller motor unit size and greater redundancy of the extraocular muscles compared to proximal limb muscles. False-positive results can occur in Lambert-Eaton myasthenic syndrome (LEMS), motor neuron disease, and in patients receiving medications that impair NMJ transmission. A false-positive response is distinguished from a true positive by serum antibody testing: anti-acetylcholine receptor antibodies (anti-AChR) are present in approximately 85 percent of generalized MG patients and are essentially diagnostic, while anti-muscle-specific kinase (anti-MuSK) antibodies account for most of the seronegative generalized cases. In current clinical practice, the edrophonium test has been substantially replaced by serological testing in most centers, but it retains a role when rapid bedside confirmation is required (for example, in a patient presenting with acute severe bulbar weakness in whom the differential diagnosis includes MG crisis) or when the clinical presentation is ambiguous and immediate physiological confirmation would change management.67
Myasthenic Crisis vs. Cholinergic Crisis. One of the most clinically consequential decisions in the management of a hospitalized MG patient who deteriorates is distinguishing between myasthenic crisis (insufficient cholinergic transmission at the NMJ due to disease progression or underdosing) and cholinergic crisis (excessive AChE inhibitor dosing producing depolarizing block at the NMJ, paradoxically worsening weakness). Both present with worsening bulbar and respiratory muscle weakness, but the accompanying muscarinic features differ: cholinergic crisis is accompanied by copious secretions (bronchorrhea, hypersalivation), miosis, bradycardia, diaphoresis, gastrointestinal (GI) cramping, and diarrhea, all reflecting muscarinic overstimulation. Myasthenic crisis is typically not accompanied by these features. In practice, when a deteriorating MG patient is intubated and mechanically ventilated, all AChE inhibitors are typically held (since they are no longer needed for oral intake and may worsen secretions), and the distinction between the two crises can be made over the subsequent hours by observing whether weakness improves (myasthenic crisis resolving with immunotherapy) or remains unchanged (cholinergic crisis resolving as drug levels fall). The edrophonium test can be used at the bedside to make the distinction when immediate clarification is required, but the risk of worsening respiratory status in a patient already in crisis makes this a high-stakes maneuver requiring senior physician oversight.7
Myasthenic crisis: worsening weakness, normal or dry secretions, normal or tachycardic heart rate, normal pupils, no GI symptoms. Often precipitated by infection, surgery, pregnancy, certain medications (aminoglycosides, fluoroquinolones, magnesium, neuromuscular blockers, beta-blockers). Treatment: intubation if needed, plasma exchange or intravenous immunoglobulin (IVIg), resume AChE inhibitors when stable. Cholinergic crisis: worsening weakness, copious secretions (bronchorrhea, hypersalivation), bradycardia, miosis, diaphoresis, GI cramping, diarrhea. Treatment: hold all AChE inhibitors, atropine for muscarinic symptoms, supportive care, ventilation if needed.
The CNS (central nervous system)-penetrating AChE inhibitors are tertiary amines that cross the BBB (blood-brain barrier) and augment cholinergic transmission in the central nervous system. This property is therapeutically exploited in two entirely different clinical contexts: physostigmine reverses the CNS effects of anticholinergic overdose, while the cholinesterase inhibitors approved for Alzheimer's disease (AD) target the cholinergic deficit in the basal forebrain projection system. Understanding both groups requires clarity on their ADME (absorption, distribution, metabolism, and excretion) profiles, selectivity differences, and the clinical endpoints that define their use.
Physostigmine. Physostigmine is a naturally occurring carbamate alkaloid isolated from the Calabar bean (Physostigma venenosum) and is the oldest AChE inhibitor in clinical use. As a tertiary amine, it crosses the blood-brain barrier (BBB) readily and is the only rapidly acting, reversible AChE inhibitor that reliably reverses the central nervous system (CNS) manifestations of anticholinergic toxidrome: confusion, agitation, delirium, and hallucinations caused by overdose of antihistamines, tricyclic antidepressants (TCAs), antipsychotics, belladonna alkaloids, and other muscarinic antagonists with CNS penetration. The mechanism is straightforward: by inhibiting central AChE, physostigmine raises ACh levels at CNS muscarinic M1 (subtype 1) receptors, reversing the effects of muscarinic blockade. The onset of action is rapid (2 to 5 minutes IV), and the duration is short (30 to 60 minutes) due to its hydrolysis and redistribution, which means repeated dosing or an infusion may be required.
Physostigmine Risks and Contraindications. Physostigmine carries its own risks in the context of anticholinergic overdose: if the causative agent is a tricyclic antidepressant (TCA), physostigmine can precipitate seizures and fatal cardiac arrhythmias by augmenting cholinergic tone in a setting where the cardiac sodium channel blockade and QRS (electrocardiographic QRS complex) prolongation of TCA toxicity are already present. For this reason, physostigmine is contraindicated in TCA overdose, and its use requires careful ECG (electrocardiogram) monitoring and exclusion of QRS prolongation before administration. In the absence of TCA involvement, physostigmine at 0.5 to 2.0 mg IV slowly is the treatment of choice for severe anticholinergic delirium that does not respond to supportive care.8
Donepezil. Donepezil is a piperidine-based, reversible AChE inhibitor that is highly selective for AChE over BuChE and is the most widely prescribed AD pharmacotherapy. It is available in 5 mg and 10 mg tablets and a 23 mg high-dose formulation approved for moderate-to-severe AD. Oral bioavailability is approximately 100 percent, with peak plasma concentrations reached in 3 to 4 hours and a terminal half-life of approximately 70 to 80 hours, allowing once-daily dosing. Donepezil is extensively metabolized by CYP2D6 (cytochrome P450 enzyme 2D6) and CYP3A4 (cytochrome P450 enzyme 3A4), and clinically significant interactions exist with potent inhibitors of these enzymes: paroxetine and fluoxetine for CYP2D6; ketoconazole and clarithromycin for CYP3A4. When these inhibitors are co-administered, donepezil plasma levels rise and the risk of cholinergic side effects increases, including nausea, vomiting, diarrhea, and vivid nightmares. The gastrointestinal (GI) side effects, which reflect M3 (muscarinic subtype 3)-mediated increases in GI motility, are substantially reduced by taking donepezil at bedtime rather than in the morning.9
Donepezil Dosing and Interactions. The 23 mg dose of donepezil is associated with a higher rate of GI adverse effects than the 10 mg dose without a proportionate increase in cognitive benefit in most patients; its use should be reserved for patients who can tolerate it and have clear disease progression on 10 mg. Donepezil has a clinically relevant drug-drug interaction with succinylcholine, which it prolongs through inhibition of the BuChE-independent component of succinylcholine metabolism; this interaction is modest but should be noted in patients scheduled for procedures requiring neuromuscular blockade (NMB).9
Rivastigmine. Rivastigmine is a carbamate derivative that inhibits both AChE and BuChE with roughly equal potency, distinguishing it from donepezil and galantamine. The dual inhibition rationale is that BuChE expression in the AD brain increases as neurodegeneration progresses and AChE expression declines, so inhibiting BuChE may provide additional cholinergic augmentation in advanced disease. Whether this dual mechanism translates to meaningful clinical superiority over selective AChE inhibitors has not been definitively established in comparative trials, but the argument remains plausible mechanistically. Rivastigmine is available as oral capsules and a transdermal patch (Exelon Patch 4.6 mg/24h, 9.5 mg/24h, and 13.3 mg/24h); the transdermal route achieves substantially lower peak plasma concentrations with similar area under the curve (AUC) exposure compared to oral dosing, reducing GI adverse effects to a level comparable to placebo in trials.10 Rivastigmine is not significantly metabolized by CYP (cytochrome P450) enzymes, making it relatively free of pharmacokinetic drug-drug interactions through that route; instead, it is hydrolyzed by cholinesterases themselves. This CYP-independence is a practical advantage in AD patients who typically carry a high polypharmacy burden. Rivastigmine is also approved for dementia associated with Parkinson's disease (PD), where the cholinergic deficit in the cortical projection system contributes to cognitive impairment independently of the dopaminergic motor deficit.9
Galantamine. Galantamine is an AChE inhibitor with a unique secondary mechanism: it is also a positive allosteric modulator (PAM) of nicotinic AChRs (nAChRs), specifically the alpha4-beta2 subtype. The PAM activity enhances the response of nAChRs to endogenous ACh without directly activating them, a mechanism distinct from agonism. The theoretical advantage is that, by potentiating nicotinic receptor responses in the cortex and hippocampus, galantamine may augment cholinergic neurotransmission through both muscarinic (via AChE inhibition) and nicotinic (via PAM activity) pathways simultaneously. Whether this dual mechanism provides clinically meaningful benefits beyond those of selective AChE inhibition has not been convincingly demonstrated. Galantamine is available in immediate-release twice-daily formulations and an extended-release once-daily capsule. It is metabolized by CYP2D6 and CYP3A4, creating the same potential for pharmacokinetic interactions as donepezil. CYP2D6 poor metabolizers, who lack functional CYP2D6 and comprise approximately 5 to 10 percent of the European-descent population, may achieve substantially higher galantamine plasma levels, increasing the risk of dose-dependent cholinergic side effects; dosing adjustments or selection of an alternative agent should be considered in this population.11
Donepezil: AChE-selective; once daily; CYP2D6/3A4 substrate; bedtime dosing reduces GI effects; 23 mg dose rarely needed; interacts with succinylcholine. Rivastigmine: AChE + BuChE dual inhibitor; transdermal patch preferred (lowest GI adverse effects); no CYP metabolism; approved for PD dementia. Galantamine: AChE inhibitor + nAChR PAM; CYP2D6/3A4 substrate; dose reduction in CYP2D6 poor metabolizers. All three: modest symptomatic benefit (approximately 1.5 to 3 point MMSE improvement), do not slow disease progression, GI adverse effects class-wide, cholinergic toxicity possible at high doses.
The cholinomimetic drug class, encompassing both direct muscarinic agonists and AChE inhibitors, generates clinically important drug-drug interactions through both pharmacokinetic (CYP enzyme-mediated) and pharmacodynamic (additive or antagonistic cholinergic effects) mechanisms. Recognizing these interactions and understanding when to adjust doses, choose alternative agents, or monitor for specific adverse effects is central to safe prescribing in the settings where these drugs are used.
Pharmacokinetic Interactions with CYP Substrates. Among the AChE inhibitors used for AD (Alzheimer's disease), donepezil and galantamine are metabolized by CYP2D6 (cytochrome P450 enzyme 2D6) and CYP3A4 (cytochrome P450 enzyme 3A4); cevimeline, among the direct agonists, is also a CYP2D6 and CYP3A4 substrate. Potent inhibitors of CYP2D6 include fluoxetine, paroxetine, bupropion, quinidine, and terbinafine; potent CYP3A4 inhibitors include azole antifungals (ketoconazole, itraconazole, voriconazole), macrolide antibiotics (clarithromycin, erythromycin), ritonavir and other HIV (human immunodeficiency virus) protease inhibitors, and grapefruit juice. When any of these inhibitors is co-administered with donepezil, galantamine, or cevimeline, plasma levels of the cholinomimetic are increased, heightening the risk of cholinergic adverse effects: nausea, vomiting, diarrhea, bradycardia, and in severe cases, syncope or bronchospasm. Conversely, CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort) reduce plasma levels of these drugs, potentially diminishing therapeutic effect. Rivastigmine avoids these interactions by virtue of its cholinesterase-mediated hydrolysis rather than CYP metabolism, which makes it a preferable option in patients on complex polypharmacy regimens involving CYP modulators.11
Pharmacodynamic Interactions: Additive Cholinergic Effects. Any drug that increases cholinergic tone at muscarinic or nicotinic synapses will have additive effects with cholinomimetic agents. The combination of an AChE inhibitor (for AD or MG) with a direct muscarinic agonist (such as bethanechol for urinary symptoms) can produce excessive muscarinic stimulation with bradycardia, bronchospasm, gastrointestinal (GI) cramping, and hypersalivation. Similarly, the combination of pyridostigmine for MG with ophthalmic pilocarpine for glaucoma can produce systemic cholinergic effects if pilocarpine is systemically absorbed (which is normally minimal but may be increased with damaged corneal epithelium). Among prescription drugs, cardiac glycosides (digoxin) can cause additive bradycardia with AChE inhibitors through complementary M2 (muscarinic subtype 2) receptor-mediated slowing of the sinoatrial (SA) node; this combination requires heart rate monitoring, particularly at higher digoxin concentrations. Beta-blockers further compound the bradycardic effect of AChE inhibitors and should be used with caution in patients on donepezil or other AD agents.1112
Pharmacodynamic Interactions: Cholinomimetic Antagonism by Anticholinergic Drugs. The therapeutic effects of AChE inhibitors in AD are substantially attenuated or reversed by co-administration of muscarinic antagonists, a drug-drug interaction that is paradoxically common in clinical practice. Tricyclic antidepressants, first-generation antihistamines (diphenhydramine, hydroxyzine), bladder antimuscarinics (oxybutynin, tolterodine), antiparkinsonian anticholinergics (benztropine, trihexyphenidyl), antipsychotics with high anticholinergic burden (olanzapine, clozapine, chlorpromazine), and many other drug categories carry muscarinic antagonist activity that directly opposes the intended effect of AChE inhibitors in AD. Multiple scoring tools, including the Anticholinergic Cognitive Burden (ACB) scale and the Anticholinergic Risk Scale (ARS), have been developed to quantify the cumulative anticholinergic load in patients on multiple medications. Regular medication review to identify and remove unnecessary anticholinergic agents is as clinically relevant as the AChE inhibitor dose itself in optimizing cognitive pharmacotherapy. Prescribers should be aware that some of the most commonly used drugs in older adults carry substantial anticholinergic burden and should be deprescribed when AD is diagnosed and AChE inhibitor therapy is initiated.11
Neuromuscular Junction Interactions. AChE inhibitors prolong the action of depolarizing NMBAs (neuromuscular blocking agents; succinylcholine and mivacurium) at the NMJ (neuromuscular junction) by inhibiting the BuChE and AChE responsible for their hydrolysis, and may convert a non-depolarizing block to a mixed or paradoxically enhanced block if used inappropriately in the context of NMB (neuromuscular blockade) reversal when the block is not sufficiently deep. The clinically relevant interaction is that patients receiving long-term AChE inhibitor therapy for MG or AD who undergo general anesthesia may show prolonged response to succinylcholine, and anesthesiologists must be informed of current cholinomimetic medications before NMB agent selection. Conversely, non-depolarizing NMBAs (rocuronium, vecuronium, cisatracurium) can unmask latent MG or precipitate a myasthenic exacerbation in patients with subclinical disease, providing an important perioperative diagnostic clue. The aminoglycoside antibiotics (gentamicin, tobramycin, amikacin) can also impair NMJ transmission by blocking presynaptic calcium channels and reducing ACh quantal release, a pharmacodynamic interaction that can precipitate MG exacerbation or worsen residual NMB in the postoperative period.45
CYP2D6/3A4 inhibitors + donepezil/galantamine/cevimeline: increased cholinergic toxicity risk; consider rivastigmine in high-polypharmacy patients. CYP3A4 inducers (rifampin, carbamazepine): reduced donepezil/galantamine efficacy. Digoxin + AChE inhibitors: additive bradycardia; monitor heart rate. Beta-blockers + AChE inhibitors: additive bradycardia. Anticholinergic drugs + AChE inhibitors for AD: directly oppose each other; deprescribe anticholinergics when AChE inhibitor initiated. Succinylcholine in AChE inhibitor-treated patients: prolonged NMB; inform anesthesiologist. Aminoglycosides: impair NMJ transmission; can precipitate MG exacerbation.
Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-178.
doi:10.1002/nau.10052Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. Arch Intern Med. 1999;159(2):174-181.
doi:10.1001/archinte.159.2.174Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing — 1999. Am J Respir Crit Care Med. 2000;161(1):309-329.
doi:10.1164/ajrccm.161.1.ats11-99Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375(26):2570-2581.
doi:10.1056/NEJMra1602678Engel AG. Current status of the congenital myasthenic syndromes. Neuromuscul Disord. 2012;22(2):99-111.
doi:10.1016/j.nmd.2011.10.009Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord. 2006;16(7):459-467.
doi:10.1016/j.nmd.2006.05.006Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419-425.
doi:10.1212/WNL.0000000000002790Watkins JW, Schwarz ES, Arroyo-Plasencia AM, Mullins ME. The use of physostigmine by toxicologists in anticholinergic toxicity. J Med Toxicol. 2015;11(2):179-184.
doi:10.1007/s13181-014-0452-xBirks JS. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;(1):CD005593.
doi:10.1002/14651858.CD005593Winblad B, Grossberg G, Frolich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 2007;69(4 Suppl 1):S14-S22.
doi:10.1212/01.wnl.0000281847.17519.e0Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. Clin Pharmacokinet. 2013;52(4):225-241.
doi:10.1007/s40262-013-0038-9Salahudeen MS, Nishtala PS. An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practice. Saudi Pharm J. 2017;25(2):165-175.
doi:10.1016/j.jsps.2016.07.002